Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyra Therapeutics

7.90
-0.6500-7.60%
Post-market: 7.900.00000.00%19:42 EDT
Volume:59.74K
Turnover:482.62K
Market Cap:12.63M
PE:-0.13
High:8.52
Open:8.48
Low:7.85
Close:8.55
Loading ...

Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results

TIPRANKS
·
02 Jun

Lyra Therapeutics Shares Soar 563% to $32 Premarket After Rhinosinusitis Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
02 Jun

Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints

MT Newswires Live
·
02 Jun

Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Reuters
·
02 Jun

Why Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket Today

CoinMarketCap
·
02 Jun

Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint

TIPRANKS
·
02 Jun

Lyra Therapeutics Reports Positive Results From the Enlighten 2 Phase 3 Trial of Lyr-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (Crs)

THOMSON REUTERS
·
02 Jun

Lyra Therapeutics Inc - Lyr-210 Well-Tolerated With Safety Profile Similar to Sham Control

THOMSON REUTERS
·
02 Jun

Lyra Therapeutics trading halted, news pending

TIPRANKS
·
28 May

US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says Expert

Benzinga
·
20 May

Lyra Therapeutics Announces Reverse Stock Split Decision

TIPRANKS
·
20 May

Lyra Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
20 May

Lyra Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Lyra Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
07 May

Lyra Therapeutics Q1 EPS $(0.13) Beats $(0.15) Estimate, Sales $183.00K Miss $240.00K Estimate

Benzinga
·
07 May

Lyra Therapeutics Q1 EPS USD -0.13

THOMSON REUTERS
·
07 May

Lyra Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
25 Apr

Lyra Therapeutics Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), aTyr Pharma (ATYR) and Lyra Therapeutics (LYRA)

TIPRANKS
·
14 Mar

Lyra Therapeutics FY 2024 GAAP EPS $(1.43) Misses $(1.38) Estimate, Sales $1.534M Beat $1.524M Estimate

Benzinga
·
14 Mar